- Oops!Something went wrong.Please try again later.
The primary efficacy endpoint of this trial was the percent change from baseline in the modified Eczema Area and Severity Index (mEASI) score at week four.
The trial achieved its primary endpoint with statistical significance, which corresponded to a 74.4% reduction in mEASI score from baseline in ATI-1777 arm compared to a 41.4% reduction in vehicle arm.
In addition, positive trends in favor of ATI-1777 were observed in key secondary efficacy endpoints, such as improvement in itch, percent of mEASI-50 responders, IGA responder analysis, and reduction in BSA impacted by the disease.
ATI-1777 was generally well-tolerated. No serious adverse events were reported. One treatment-related adverse event, application site pruritus, was reported in one subject in the ATI-1777 arm.
Final trial results will be submitted for publication in a peer-reviewed scientific journal.
Management will host a conference call and webcast today at 8:00 AM ET.
Price Action: ACRS shares are up 2.9% at $23.02 during the premarket session on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.